Ceddia S, Codacci-Pisanelli G (2021) Treatment of brain metastases in ALK-positive non-small cell lung cancer. Crit Rev Oncol Hematol 165:103400

Article  PubMed  Google Scholar 

Peters S, Bexelius C, Munk V, Leighl N (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139–162

Article  PubMed  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2023) NCCN guidelines insights: non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw 21(4):340–350

Article  CAS  PubMed  Google Scholar 

Nelson TA, Wang N (2023) Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic Lymphoma kinase (ALK)-positive Disease. Transl Lung Cancer Res 12(2):379–392

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buss EJ, Wang TJC (2018) Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine? Transl Lung Cancer Res 7(Suppl 4):S318–S20

Article  PubMed  PubMed Central  Google Scholar 

Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129

Article  CAS  PubMed  Google Scholar 

Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A (2015) Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res 35(11):5797–5806

CAS  PubMed  Google Scholar 

Liao HR, Chiang CL, Shen CI, Chen CJ, Yang HC, Wu HM et al (2022) EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases. J Neurooncol 159(3):675–684

Article  CAS  PubMed  Google Scholar 

Matsunaga S, Shuto T (2021) Outcomes of gamma knife radiosurgery for brain metastases from anaplastic lymphoma kinase rearrangement-positive and EGFR mutation-positive non-small cell lung cancer. Cureus 13(12):e20398

PubMed  PubMed Central  Google Scholar 

Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L et al (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6(7):1287–1289

Article  PubMed  Google Scholar 

Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70(3):399–405

Article  CAS  PubMed  Google Scholar 

Chen YC, Lee CC, Chiang CL, Yang HC, Wu HM, Chen CJ et al Combined BBB-penetrant tyrosine kinase inhibitor and intracranial radiotherapy versus BBB-penetrant tyrosine kinase inhibitor alone for the treatment of EGFR-mutated non-small cell lung cancer patients with brain metastases. https://doi.org/10.21203/rs.3.rs-2960400/v1

Cho A, Untersteiner H, Hirschmann D, Shaltout A, Gobl P, Dorfer C et al (2020) Gamma knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy. Cancers (Basel). 12(12)

Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D et al (2022) Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40(5):492–516

Article  CAS  PubMed  Google Scholar 

Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C et al (2022) Brain metastases in EGFR- and ALK-Positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation. J Thorac Oncol 17(1):116–129

Article  CAS  PubMed  Google Scholar 

Zhang Z, Guo H, Lu Y, Hao W, Han L (2019) Anaplastic lymphoma kinase inhibitors in non-small cell Lung cancer patients with brain metastases: a meta-analysis. J Thorac Dis 11(4):1397–1409

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29(15):e443–e445

Article  PubMed  Google Scholar 

Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR et al (2016) Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17(4):452–463

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell Lung cancer. N Engl J Med 377(9):829–838

Article  CAS  PubMed  Google Scholar 

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS et al (2018) Brigatinib versus crizotinib in ALK-positive non-small-cell Lung cancer. N Engl J Med 379(21):2027–2039

Article  CAS  PubMed  Google Scholar 

Kodama T, Hasegawa M, Takanashi K, Sakurai Y, Kondoh O, Sakamoto H (2014) Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74(5):1023–1028

Article  CAS  PubMed  Google Scholar 

Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G et al (2020) First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 383(21):2018–2029

Article  CAS  PubMed  Google Scholar 

Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR et al (2021) Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 32(5):620–630

Article  CAS  PubMed  Google Scholar 

Tan AC, Itchins M, Khasraw M (2020) Brain metastases in lung cancers with emerging targetable fusion drivers. Int J Mol Sci 21(4)

Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C (2015) Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for Disease assessment and management. Lung Cancer 88(3):355–359

Article  PubMed  Google Scholar 

Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA et al (2016) Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96(5):1060–1069

Article  PubMed  Google Scholar 

Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810–3816

Article  PubMed  PubMed Central  Google Scholar 

Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A et al (2018) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 1(1):CD003869

PubMed  Google Scholar 

Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B (2015) Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol 16(13):e510–e521

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW et al (2016) Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 34(24):2858–2865

Article  CAS  PubMed  Google Scholar 

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33(17):1881–1888

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM et al (2018) Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res 24(12):2758–2770

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanchez-Herrero E, Serna-Blasco R, Ivanchuk V, Garcia-Campelo R, Domine Gomez M, Sanchez JM et al (2021) NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Mol Oncol 15(9):2363–2376

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM et al (2020) MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res 26(11):2535–2545

Article  CAS  PubMed  PubMed Central  Google Scholar